B4Bio

B4Bio is a biotechnology company dedicated to developing next-generation biologics for the treatment of metabolic diseases, with a primary focus on obesity, type 2 diabetes, and MASH. The company utilizes its proprietary 'Better Biology, Better Biologics' (B4) approach to engineer therapies that offer superior clinical outcomes and improved patient experiences. Founded by industry experts from Eli Lilly and backed by prominent venture capital firms, B4Bio combines deep expertise in metabolic signaling with advanced protein engineering. Their pipeline is currently in the pre-clinical stage, targeting well-validated and novel pathways within the metabolic landscape. The company aims to address the limitations of current incretin-based therapies by optimizing molecular design for better tolerability and efficacy.